Compare Agilysys Inc (AGYS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Novo Nordisk A/S — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 69.3× Agilysys Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | NVO | |
|---|---|---|
Market Cap | $3.00B | $207.85B |
Sector | Technology | Health |
52-Week High | $141.12 | $63.98 |
52-Week Low | $62.19 | $35.29 |
Enterprise Value | $2.90B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $107.35, up 0.35% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q1 and Q2 2026 earnings beats, record subscription revenue growth, and improved FY27 guidance. Technical indicators suggest bullish momentum with support at $106 and resistance at $108. The company's hospitality software solutions are gaining traction through partnerships and AI-driven innovation.
Outlook remains positive with 100% analyst buy ratings and $118.33 consensus price target representing 10.2% upside. Key opportunities include subscription revenue growth and Marriott deployment progress, while risks include execution challenges and competitive pressures in the hospitality technology sector.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
